Overview

Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement

Status:
Completed
Trial end date:
2019-01-30
Target enrollment:
Participant gender:
Summary
The objective of this pilot study is to assess whether Myrbetriq™ will improve post-operative ureteral pain and discomfort, reduce bladder storage symptoms and increase quality of life following ureteral stenting.
Phase:
Phase 2
Details
Lead Sponsor:
Southern Illinois University
Collaborators:
Astellas Scientific & Medical Affairs, Inc.
Sisters of the Third Order of St. Francis
Treatments:
Mirabegron